1
|
Frustaci S, Lo Re G, Crivellari D, De Paoli A, Galligioni E, Franchin G, Tumolo S, Monfardini S. Retrospective Analysis of the Cyvadic Regimen in Advanced Soft Tissue Sarcomas. Tumori 2018; 75:152-5. [PMID: 2741222 DOI: 10.1177/030089168907500215] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We performed a retrospective review of our data obtained with the original CYVADIC regimen in 31 consecutive patients with advanced soft tissue sarcomas. The treatment consisted of cyclophosphamide 500 mg/m2 i.v. on day 1, vincristine 1.5 mg/m2 in days 1 and 5, doxorubicin 50 mg/m2 i.v. on day 1, and dacarbazine 250 mg/m2 i.v. from days 1 to 5, repeated every 3 weeks. An objective response was observed in 11/31 patients (35.5%). There were 2 complete remissions (6.5%) lasting 23 and 2 months respectively and 9 partial responses (median duration 7 months, range 1–23). No change was observed in 14 patients, and 6 patients showed progression after a median of 2 cycles of chemotherapy. Toxicity was similar to that already described with this regimen, with alopecia, nausea, vomiting and myelosuppression being the most important side effects. In particular, the median WBC nadir was 1,900/mm3 (range 400–3,600/mm3) whereas the platelet nadir was 181,000/mm3 (range 80,000–358,000/mm3); no patient developed congestive heart failure, and no treatment related death was observed. Still today, after 10 years of use, the CYVADIC regimen is very widely employed as a standard treatment for recurrent or metastatic soft tissue sarcomas, although the original positive results have been confirmed only by a few authors. In our retrospective analysis of a totally unselected population of patients, we too observed a lower activity which is, however, according to a recent review, similar to the mean value of responses obtained in the whole population of treated patients reported in the literature.
Collapse
Affiliation(s)
- S Frustaci
- Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Crivellari D, Galligioni E, Frustaci S, Foladore S, Lo Re G, Morassut S, Monfardini S. Cisplatin and Mitomycin C in Advanced Chemotherapy-Refractory Breast Cancer. Tumori 2018; 76:234-7. [PMID: 2114683 DOI: 10.1177/030089169007600305] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A combination of platinum (100 mg/m2 in a 24-h continuous i.v. infusion) and mitomycin C (10 mg/m2 i.v. push at the end of the cisplatin infusion) was administered in 20 patients with advanced breast cancer refractory to conventional treatments (CMF and anthracycline-containing regimens, hormonal therapies). The response rate was 20% (4/20), including one complete response of lung metastases which lasted 12 months. Median duration of partial responses was 4 months. Major toxicity was gastrointestinal and it was superimposable to that observed with other cisplatin-containing regimens. A marked and prolonged asthenia was reported in 6/20 patients (30%), and the regimen's compliance was poor. We conclude that at these doses and schedule, the cisplatin and mitomycin C combination has a limited efficacy in advanced breast cancer patients, and its use is not recommended in pretreated patients.
Collapse
Affiliation(s)
- D Crivellari
- Medical Oncology Department, Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
| | | | | | | | | | | | | |
Collapse
|
3
|
Veronesi A, Talamini R, Longhi S, Crivellari D, Galligioni E, Tirelli U, Trovò MG, Magri MD, Frustaci S, Figoli F, Zagonel V, Tumolo S, Grigoletto E. Carcinoembryonic Antigen (CEA) in the Follow-Up of Disease-Free Breast Cancer Patients. Tumori 2018; 68:477-80. [PMID: 7168012 DOI: 10.1177/030089168206800605] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Carcinoembryonic antigen (CEA) assays (2536) were performed in 380 disease-free breast cancer patients after radical mastectomy. In the 334 evaluable patients with 3 or more determinations, the overall relapse rate after a median follow-up of 29 months was 11 %. Of 203 patients with normal CEA values, 19 (9.3 %) relapsed. In the 50 patients with the highest CEA value greater than 20 ng/ml, the relapse rate was 26 %; in the 12 patients with gradually increasing CEA elevations it was 50 %. However, CEA was unable to predict recurrence in N- patients. Premastectomy N+ was significantly associated with greater than 20 ng/ml or gradually increasing CEA values, suggesting the lack of an independent prognostic value of CEA in our patient population.
Collapse
|
4
|
Veronesi A, Frustaci S, Tirelli U, Galligioni E, Trovò MG, Crivellari D, Magri MD, Tumolo S, Grigoletto E. Tamoxifen Therapy in Postmenopausal Advanced Breast Cancer: Efficacy at the Primary Tumor Site in 46 Evaluable Patients. Tumori 2018; 67:235-8. [PMID: 7281242 DOI: 10.1177/030089168106700313] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Forty-six evaluable postmenopausal patients with locally advanced, inoperable T3-T4 breast carcinoma were treated with tamoxifen 10-20 mg twice daily for a period at least 6 weeks. Eight patients (17 %) had an objective response at the primary tumor site after 6 weeks of treatment. Improvement of response with a further single tamoxifen therapy was observed in 7 patients, resulting in an overall objective response in 14 of 46 (30 %). Median duration of response was 8 months (range 2-24). No response was obtained in the 5 patients with inflammatory signs. Toxicity of treatment was minimal. Median survival was 10 months (responders 17.5, non-responders 9). Tamoxifen seems to be a safe and effective treatment for locally advanced breast cancer without inflammatory signs in postmenopausal women.
Collapse
|
5
|
Frustaci S, Buonadonna A, Romanini A, Comandone A, Dalla Palma M, Gamucci T, Verusio C, Lionetto R, Dani C, Casali P, Santoro A. Increasing dose of Continuous Infusion Ifosfamide and Fixed dose of Bolus Epirubicin in Soft Tissue Sarcomas. A Study of the Italian Group on Rare Tumors. Tumori 2018; 85:229-33. [PMID: 10587022 DOI: 10.1177/030089169908500403] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Purpose To evaluate the maximum tolerated doses (MTD) of ifosfamide when given as a continuous infusion and in combination with fixed doses of bolus 4′-epidoxorubicin in advanced previously untreated adult soft tissue sarcoma patients. Methods Treatment consisted of epidoxorubicin, 60 mg/m2 days one and two, and ifosfamide, 1.5 g/m2 every 12 hrs as a 72-hr infusion, at the first level. Further levels of ifosfamide were defined as increments of 12 hrs of the same infusion program. G-CSF 300 μg/die was administered from days +7 to +14. Dose-limiting toxicity (DLT) was defined as: G4 leukopenia or thrombocytopenia of ≥5 days; any G3 neuro or nephrotoxicity; G4 toxicity of any kind. Patients had to complete at least 2 consecutive cycles, and MTD was defined as the level in which 20% of patients developed a DLT; 10-15 patients were entered in each level. Results First level: overall, 13 patients entered, 3 were not assessable for MTD, and only one developed a DLT. Second level: 18 patients entered, 3 were not assessable for MTD. Hematologic DLT was observed in 3/15 assessable patients. Therefore, the MTD was found at the ifosfamide level of 10.5 g/m2 given in 84 hrs. Eight patients of 29 assessable for response achieved an objective response: 1 complete and 7 partial. The overall response rate was 28% (95% CI: 13-47%). Conclusions If we accept 4-day G4 leukopenia as a reliable cutoff for safety, ifosfamide intensification cannot be substantially exploited over already available schedules with the combination of ifosfamide and anthracyclines.
Collapse
Affiliation(s)
- S Frustaci
- Divisione di Oncologia Medica, Centro di Riferimento Oncologico, Aviano, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Tirelli U, Frustaci S, Galligioni E, Veronesi A, Trovò MG, Magri DM, Crivellari D, Roncadin M, Tumolo S, Grigoletto E. Medical Treatment of Metastatic Renal Cell Carcinoma. Tumori 2018; 66:235-40. [PMID: 7445105 DOI: 10.1177/030089168006600212] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Thirty five patients with metastatic RCC were observed over a 57 months period in our Division of Radiotherapy and Medical Oncology, and 30 are evaluable for this analysis. MPA was selected as primary treatment agent in 23 patients, VLB singly, in combination with MPA or in combination with CCNU was used in 1.4 and 2 patients. With MPA the TR rate was 3/23 (1 CR and 2 PR). Duration of response for the patient with CR was 6 months whereas for the patients with PR was 21 and 14 months respectively. 4 additional patients showed NC. With VLB-MPA the TR rate was 1/4 (1 PR). Duration of PR was 3 months. The median duration of survival for the 11 patients with CR, PR and NC was 14 months whereas for the 19 patients with NR was 7 months (p < 0.01). TES and TAM showed no or minimal activity as second treatment agents.
Collapse
|
7
|
Rupolo M, Berretta M, Buonadonna A, Stefanovski P, Bearz A, Bertola G, Canzonieri V, Morassut S, Frustaci S. Metastatic Angiosarcoma of the Spleen. A Case Report and Treatment Approach. Tumori 2018; 87:439-43. [PMID: 11989602 DOI: 10.1177/030089160108700617] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
We report a case of a 28-year-old man with angiosarcoma of the spleen and liver metastases. The aim of this paper is to underline the importance of planned splenectomy in these patients even if they have metastatic disease, and to propose an intensive chemotherapy regimen consisting of anthracyclines, ifosfamide and mesna with G-CSF support.
Collapse
Affiliation(s)
- M Rupolo
- Divisione di Oncologia Medica, Centro di Riferimento Oncologico, IRCCS, Istituto Nazionale Tumori, Aviano, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Tirelli U, Veronesi A, Galligioni E, Trovò MG, Magri D, Frustaci S, Crivellari D, Roncadin M, Tumolo S, Grigoletto E. Clinical and Immunological Evaluation of 5 Cases of Mycosis Fungoides in Advanced Stages. Tumori 2018; 65:447-53. [PMID: 315125 DOI: 10.1177/030089167906500404] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Five patients with mycosis fungoides, hospitalized in the Division of Radiotherapy and Medical Oncology of the Ospedale Civile, Pordenone, from January 1975 to December 1978, were studied and treated as non-Hodgkin lymphomas. All patients had evidence of disseminated disease: 3 with bone marrow infiltration, 1 with splenic involvement and 1 with lymph node involvement. Three patients were treated with CVP, resulting in 2 complete remissions that lasted 18 months and 1 PR > 50% maintained for 7 months. One patient was treated with ABVD with a PR > 50% maintained for 10 months. The last patient was treated with prednisone and then with CV, but expired from pulmonary embolism after 1 cycle. Lymphocyte function, using E and EAC rosette and PHA, was evaluated before therapy in all patients: in the 2 patients who obtained a CR, an improvement in T-lymphocyte function was noted after therapy. The chromosome pattern of peripheral blood lymphocytes was altered before therapy in only one patient. Even if the follow-up period is still relatively brief, the duration of the 2 complete remissions must be stressed. In addition, a strict correlation between T-lymphocyte function and response to therapy was revealed in our study.
Collapse
|
9
|
Di Bartolomeo M, Rosato G, Banzi M, Pella N, Zampino M, Rimassa L, Maiello E, Marchetti P, Lonardi S, Labianca R, Zaniboni A, Sobrero A, Ferrari D, Bidoli P, Iaffaioli V, De Placido S, Frassineti L, Frustaci S, Nicolini M, Vernieri C, Galli F. Metformin and risk recurrence in resected stage II/III colon cancer (CC) patients (pts): subgroup analysis from the TOSCA trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Abstract
Oxaliplatin is a new, third-generation platinum complex. It has a good safety profile characterized by low hematological-gastrointestinal toxicity. No significant nephro-ototoxicity has been observed. Acute peripheral neuropathy is a common event affecting, as grade 1 or 2, 85-95% of patients. Recently, data on dysphonia toxicity, after the administration of oxaliplatin, has been reported in literature. This toxicity with acute onset can be misunderstood if not carefully looked for. However, it is self-limiting and a non-permanent (grade 1-2) neurotoxic phenomenon, which impairs transiently the quality of life of a percentage of oxaliplatin-treated patients. We report our experience in consecutive patients affected by advanced colorectal cancer treated with oxaliplatin-based chemotherapy. Overall, we observed 13 (16%) cases of dysphonia out of 81 consecutive patients treated with oxaliplatin-based chemotherapy. This toxic effect was self-limiting and all patients recovered rapidly. Nonetheless, a deeper understanding of this phenomenon is essential to give correct information to the patients.
Collapse
Affiliation(s)
- M Berretta
- Division of Medical Oncology A and 3B--National Cancer Institute, Aviano, Italy
| | | | | | | | | | | | | |
Collapse
|
11
|
Gronchi A, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos A, Palassini E, Stacchiotti S, Ferrari S, Fiore M, Casali P. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. Ann Oncol 2013; 24:817-23. [DOI: 10.1093/annonc/mds501] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Santoro A, Romanini A, Rosso A, Frustaci S, Comandone A, Apice G, De Toma D, Dogliotti L, Lionetto R, Dani C, Bruzzi P, Piolini M, Bergnolo P, Verusio C. Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors. Sarcoma 2011; 3:177-81. [PMID: 18521282 PMCID: PMC2395431 DOI: 10.1080/13577149977613] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Purpose. The prognosis of advanced soft tissue sarcoma is poor, only
a few drugs showing some activity with response rates around 15– 25%. Consequently drug
development seems mandatory to improve treatment outcome. Following previous
favourable EORTC experience, the Italian Group on Rare Tumors started a phase II study
with docetaxel to confirm the activity of this drug in soft tissue sarcoma. Patients and methods. Thirty-seven patients with soft tissue sarcoma
resistant to at least one anthracyclinecontaining regimen were enrolled in a phase II multicenter
study evaluating docetaxel 100 mg/m2
in a 1-h i.v. infusion q3
weeks. Results.Thirty-seven patients were enrolled onto this phase II study and
36 were evaluable for response. Only one partial remission was observed [2.8% with 95%
confidence interval (CI) 0.1– 16.2%]. Median progression-free and overall survival
were 42 and 350 days, respectively. Neutropenia and leukopenia as well as cutaneous
manifestations were the most common toxicities. Discussion. The results of this phase II study do not confirm a previous
EORTC repor t on the activity of docetaxel in soft tissue sarcoma, but are consistent with
other more recent phase II studies. The accumulated evidence does not justify the use of this
drug in the management of patients suffering from this disease, resistant to
anthracyclinecontaining regimens.
Collapse
Affiliation(s)
- A Santoro
- Italian Group on Rare Tumors c/o Istituto Clinico Humanitas Via Manzoni, 56 Milano Rozzano 20089 Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Stacchiotti S, Verderio P, Messina A, Morosi C, Ferraro A, Quagliuolo V, Martin J, Comandone A, Grignani G, Picci P, Frustaci S, Gronchi A, Casali PG. Tumor response and outcome in localized high-risk soft tissue sarcomas (STS) treated with preoperative chemotherapy (CHT) with or without radiation therapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
De Pas T, Rosati G, Spitaleri G, Boni C, Tucci A, Frustaci S, Scalamogna R, Radice D, Boselli S, Toffalorio F, Catania C, Noberasco C, Delmonte A, Vecchio F, de Braud F. Optimizing Clinical Care in Patients with Advanced Soft Tissue Sarcoma: A Phase II Study of a New Schedule of High-Dose Continuous Infusion Ifosfamide and Doxorubicin Combination. Chemotherapy 2011; 57:217-24. [DOI: 10.1159/000326466] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2010] [Accepted: 12/06/2010] [Indexed: 12/27/2022]
|
15
|
Grignani G, Palmerini E, Stacchiotti S, Boglione A, Ferraresi V, Frustaci S, Comandone A, Casali PG, Ferrari S, Aglietta M. A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor-α or -β (PDGFR-α/PDGFR-β): An Italian Sarcoma Group study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10060] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Gronchi A, Frustaci S, Mercuri M, Martin Broto J, Lopez-Pousa A, Mariani L, Verderio P, Quagliuolo V, Casali PG, Picci P. Localized, high-risk soft tissue sarcomas (STS) of the extremities and trunk wall in adults: Three versus five cycles of full-dose anthracyclin and ifosfamide adjuvant chemotherapy: A phase III randomized trial from the Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (GEIS). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Crivellari D, Spazzapan S, Magri M, Frustaci S, Talamini R, Lombardi D, Torrisi E, Scalone S, Miolo G, Veronesi A. Lapatinib plus capecitabine in highly pretreated HER2-positive metastatic breast cancer: A single-institution experience. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1145] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Celio L, Bajetta E, Denaro A, Bichisao E, Frustaci S, Ardizzoia A, Piazza E, Fabi A, Capobianco A, Isa L. Single-day regimen of palonosetron (PALO) and dexamethasone (DEX) for the prevention of emesis associated with moderately emetogenic chemotherapy (MEC): Subgroup analysis from a randomized phase III trial. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9620] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9620 Background: We have recently shown non-inferiority in preventing acute and delayed nausea and vomiting associated with MEC between the PALO plus 1-day DEX and PALO plus 3-day DEX regimens. Planned analysis stratified by type of chemotherapy (anthracycline + cyclophosphamide [AC] group or patients receiving at least one moderately emetogenic agent according to modified Hesketh classification) has been performed. Methods: A total of 332 chemo-naïve patients with solid tumors were randomized to receive a single IV dose of PALO 0.25 mg plus DEX 8 mg IV on day 1 of chemotherapy (arm A; n=166) or the same regimen followed by DEX 8 mg orally on days 2 and 3 (arm B; n=166). Endpoints included complete response rates (CR: no emetic episodes [EE], no rescue antiemetics; primary endpoint) and proportion of patients with no EE throughout the 5 days after the first cycle of chemotherapy. Subgroups were analyzed by two-sided chi-square test. Results: Per-protocol population included 324 patients (65% women; median age 57.5 years); 35% received AC regimens, and 65% other MEC regimens. There were no significant differences between arms in CR rates according to the type of chemotherapy: 1) CR rates on AC regimens (arm A, 55.8% versus arm B, 60.7%; p=0.599); and 2) CR rates on other MEC regimens (arm A, 68.5% versus arm B, 72%; p=0.576). No significant differences between arms were also observed in the rates of patients with no EE: 1) emesis-free patients on AC regimens (arm A, 78.8% versus arm B, 73.8%; p=0.528); 2) emesis-free patients on other MEC regimens (arm A, 83.8% versus arm B, 90%; p=0.184); 3) nausea-free patients on AC regimens (arm A, 38.5% versus arm B, 44.3%; p=0.533); and 4) nausea-free patients on other MEC regimens (arm A, 58.6% versus arm B, 64%; p=0.418). Conclusions: The single-day regimen of PALO and DEX can provide effective protection against acute and delayed emesis from AC- and MEC-based regimens while avoiding to unnecessarily prolong treatment with DEX. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. Celio
- Italian Trials in Medical Oncology (ITMO) Group; National Cancer Institute, Milan, Italy; National Cancer Institute, Aviano, Italy; San Gerardo Hospital, Monza, Italy; Sacco Hospital, Milan, Italy; Regina Elena National Cancer Institute, Rome, Italy; C.R.O.B., Rionero in Vulture, Italy; Serbelloni Hospital, Gorgonzola, Italy
| | - E. Bajetta
- Italian Trials in Medical Oncology (ITMO) Group; National Cancer Institute, Milan, Italy; National Cancer Institute, Aviano, Italy; San Gerardo Hospital, Monza, Italy; Sacco Hospital, Milan, Italy; Regina Elena National Cancer Institute, Rome, Italy; C.R.O.B., Rionero in Vulture, Italy; Serbelloni Hospital, Gorgonzola, Italy
| | - A. Denaro
- Italian Trials in Medical Oncology (ITMO) Group; National Cancer Institute, Milan, Italy; National Cancer Institute, Aviano, Italy; San Gerardo Hospital, Monza, Italy; Sacco Hospital, Milan, Italy; Regina Elena National Cancer Institute, Rome, Italy; C.R.O.B., Rionero in Vulture, Italy; Serbelloni Hospital, Gorgonzola, Italy
| | - E. Bichisao
- Italian Trials in Medical Oncology (ITMO) Group; National Cancer Institute, Milan, Italy; National Cancer Institute, Aviano, Italy; San Gerardo Hospital, Monza, Italy; Sacco Hospital, Milan, Italy; Regina Elena National Cancer Institute, Rome, Italy; C.R.O.B., Rionero in Vulture, Italy; Serbelloni Hospital, Gorgonzola, Italy
| | - S. Frustaci
- Italian Trials in Medical Oncology (ITMO) Group; National Cancer Institute, Milan, Italy; National Cancer Institute, Aviano, Italy; San Gerardo Hospital, Monza, Italy; Sacco Hospital, Milan, Italy; Regina Elena National Cancer Institute, Rome, Italy; C.R.O.B., Rionero in Vulture, Italy; Serbelloni Hospital, Gorgonzola, Italy
| | - A. Ardizzoia
- Italian Trials in Medical Oncology (ITMO) Group; National Cancer Institute, Milan, Italy; National Cancer Institute, Aviano, Italy; San Gerardo Hospital, Monza, Italy; Sacco Hospital, Milan, Italy; Regina Elena National Cancer Institute, Rome, Italy; C.R.O.B., Rionero in Vulture, Italy; Serbelloni Hospital, Gorgonzola, Italy
| | - E. Piazza
- Italian Trials in Medical Oncology (ITMO) Group; National Cancer Institute, Milan, Italy; National Cancer Institute, Aviano, Italy; San Gerardo Hospital, Monza, Italy; Sacco Hospital, Milan, Italy; Regina Elena National Cancer Institute, Rome, Italy; C.R.O.B., Rionero in Vulture, Italy; Serbelloni Hospital, Gorgonzola, Italy
| | - A. Fabi
- Italian Trials in Medical Oncology (ITMO) Group; National Cancer Institute, Milan, Italy; National Cancer Institute, Aviano, Italy; San Gerardo Hospital, Monza, Italy; Sacco Hospital, Milan, Italy; Regina Elena National Cancer Institute, Rome, Italy; C.R.O.B., Rionero in Vulture, Italy; Serbelloni Hospital, Gorgonzola, Italy
| | - A. Capobianco
- Italian Trials in Medical Oncology (ITMO) Group; National Cancer Institute, Milan, Italy; National Cancer Institute, Aviano, Italy; San Gerardo Hospital, Monza, Italy; Sacco Hospital, Milan, Italy; Regina Elena National Cancer Institute, Rome, Italy; C.R.O.B., Rionero in Vulture, Italy; Serbelloni Hospital, Gorgonzola, Italy
| | - L. Isa
- Italian Trials in Medical Oncology (ITMO) Group; National Cancer Institute, Milan, Italy; National Cancer Institute, Aviano, Italy; San Gerardo Hospital, Monza, Italy; Sacco Hospital, Milan, Italy; Regina Elena National Cancer Institute, Rome, Italy; C.R.O.B., Rionero in Vulture, Italy; Serbelloni Hospital, Gorgonzola, Italy
| |
Collapse
|
19
|
Berretta M, Bearz A, Frustaci S, Talamini R, Lombardi D, Fratino L, Lleshi A, Bonanno S, Spartà D, Palmucci S, Berretta S, Tirelli U. FOLFOX2 in the Treatment of Advanced Colorectal Cancer: A Comparison Between Elderly and Middle Aged Patients. J Chemother 2008; 20:503-508. [DOI: 10.1179/joc.2008.20.4.503] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
|
20
|
Buonadonna A, De Paoli A, Sigon R, Cannizzaro R, Canzonieri V, Boz G, Innocente R, Rossi C, De Marchi F, Frustaci S. Neoadjuvant chemotherapy (CT) and postoperative chemoradiation (PCRT) in locally advanced, resectable, gastric cancer (LAGC). Preliminary results of a pilot study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15078 Background: Curative surgery is achieved in fewer than 50% of patients (pts) in LAGC. PCRT has shown significant improvement in disease control and survival but a limited impact on metastatic disease. To improve this results, a combined modality approach, including IORT, was planned. Methods: Pts with resectable LAGC (stage T3–4 and/or N+) were eligible. EGDS, EUS, abdomen CT were used for staging. 3 cycles of ECF (Epirubicin 50mg/mq, q 3wks; Cisplatin 60mg/mq, q 3wks and 21-day c.i. 5-FU 200mg/mq/day) were planned before radical surgery. IORT (10–15 Gy) included the high risk area defined at surgery. Postop RT included gastric area, anastomosis, duodenal stump and draining lymph node stations. RT (41.4–45 Gy in 23–25 fractions) and concurrent c.i. 5-FU (200 mg/mq/day) were administered. An oral caloric intake >= 1500 Kcal was provided. Results: From June 2001 to December 2006, 22 pts (13 M and 9 F), median age 64 yrs (41–74), with uT3N1 (21pts) and uT2N1 (1pt), entered the study. Tumor location was proximal in 10, lower in 8 and middle in 4 pts, respectively. All pts underwent the planned neoadjuvant ECF with a median of 3 cycles (range 3–5). Toxicity was moderate (<= grade 3) without toxic deaths: nausea and vomiting in 3%, mucositis in 3%, hematological in 7%. Twenty/22 pts underwent surgery (in progress in 2 pts) and 15 (75%) had R0 resection. Tumor downstaging was reported in 9/20 (45%) pts (8 pT2, 1pT1). IORT with 12.5 Gy (10–15 Gy) was given to 12 pts and 12 pts had PCRT. Eight pts were excluded from PCRT for postop complications (2 pts), disease progression (3 pts) or pN3 (3 pts). All 12 pts completed RT with a median dose of 41.4 Gy (41.4–56Gy), but 3 (25%) required RT interruption and 5 pts (40%) also definitive 5-FU interruption (overall PCRT compliance of 60%). Major toxicity from PCRT consisted of G3 asthenia and anorexia, requiring parenteral nutrition. Conclusions: Neoadjuvant CT confirmed feasible in LAGC and resulted in a substantial downstaging with a favourable R0 resection rate. Combined modality approach with IORT and PCRT appears attractive, but limited compliance to PCRT was observed. A definitive evaluation and data on disease control and survival will be reported. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | - R. Sigon
- National Cancer Institute, Aviano, Italy
| | | | | | - G. Boz
- National Cancer Institute, Aviano, Italy
| | | | - C. Rossi
- National Cancer Institute, Aviano, Italy
| | | | | |
Collapse
|
21
|
Berretta M, Bearz A, Frustaci S, Buonadonna A, La Mura N, Malaguarnera M, Fulvi A, Shehu I, Tirelli U. FOLFOX2 regimen in the treatment of advanced colorectal cancer: a comparison between elderly and young patients. Ann Oncol 2006; 17:1606-7. [PMID: 16728481 DOI: 10.1093/annonc/mdl098] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Berretta M, Rupolo M, Buonadonna A, Canzonieri V, Brollo A, Morra A, Berretta S, Bearz A, Tirelli U, Frustaci S. Metastatic angiosarcoma of the kidney: a case report with treatment approach and review of the literature. J Chemother 2006; 18:221-4. [PMID: 16736893 DOI: 10.1179/joc.2006.18.2.221] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Angiosarcomas are rare soft tissue malignancies. Typically they originate from the skin of the scalp or face, whereas visceral sarcomas are very rare. We report the case of a 67-year-old man affected by a large angiosarcoma of the kidney. After surgical removal, a rapid peritoneal, visceral and cutaneous diffusion developed. Palliative chemotherapy, based on anthracycline and ifosfamide, which are normally used to treat all other high-grade spindle cell sarcomas, was totally inactive. On the basis of these results and of the biological characteristics of these rare neoplasms it is mandatory to develop other therapeutic approaches. Antiangiogenetic agents are of interest for this disease due to the peculiar origin of the cells of these sarcomas.
Collapse
Affiliation(s)
- M Berretta
- Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
De Paoli A, Chiara S, Luppi G, Friso ML, Beretta GD, Del Prete S, Pasetto L, Santantonio M, Sarti E, Mantello G, Innocente R, Frustaci S, Corvò R, Rosso R. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 2005; 17:246-51. [PMID: 16282246 DOI: 10.1093/annonc/mdj041] [Citation(s) in RCA: 99] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND The aim of the study was to evaluate tolerance and efficacy of preoperative treatment with capecitabine in combination with radiation therapy (RT) in patients with locally advanced, resectable, rectal cancer. PATIENTS AND METHODS Fifty-three patients with potentially resectable T3, N0-2 (87%) and T4, N0-2 (13%) rectal cancer were treated with capecitabine (825 mg/m2, twice daily for 7 days/week) and concomitant RT (50.4 Gy/28 fractions). Patients underwent surgery after 6-8 weeks followed, upon physician's indications, by 4-months adjuvant capecitabine. The primary end point was to determine the rate of pathologic complete response. Secondary end points were to assess the rate of clinical response and the safety profile. RESULTS All patients but two completed the RT programme and 47 (89%) received 81%-100% of the capecitabine dose (100% of dose in 72% patients, 81%-95% in 17% patients and 48%-74% in 11% of patients). No patient had grade 4 toxicity. Grade 3 toxicity occurred in six patients (11%) and consisted mainly of leucopenia (4%) and hand-foot syndrome (4%). Mild or moderate toxicity was common and included leucopenia (72%), diarrhea (40%), proctitis (34%) and skin toxicity (20%). The overall clinical response rate was 58% and the downstaging rate was 57%, with a pathologic complete response rate of 24%. Among 34 patients with low-lying tumors (<or=5 cm from anal verge), 20 (59%) had a sphincter-saving operation. CONCLUSIONS Preoperative chemoradiation with capecitabine and RT appeared to be effective in locally advanced resectable, rectal cancer. The favorable safety profile of the combination might warrant the use of capecitabine and RT with other effective new drugs.
Collapse
Affiliation(s)
- A De Paoli
- Department of Radiation Oncology, C.R.O. - National Cancer Institute, Aviano, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
De Paoli A, Chiara S, Luppi G, Friso ML, Beretta G, Delprete S, Pasetto L, Frustaci S, Santantonio M, Corvò R. A phase II study of capecitabine (CAP) and pre-operative radiation therapy (RT) in resectable, locally advanced rectal cancer (LARC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. De Paoli
- National Cancer Institute-CRO, Aviano, Italy; National Institute for Cancer Research, Genova, Italy; University Hospital, Modena, Italy; University Hospital, Padova, Italy; Ospedali Riuniti, Bergamo, Italy; General Hospital, Ancona, Italy
| | - S. Chiara
- National Cancer Institute-CRO, Aviano, Italy; National Institute for Cancer Research, Genova, Italy; University Hospital, Modena, Italy; University Hospital, Padova, Italy; Ospedali Riuniti, Bergamo, Italy; General Hospital, Ancona, Italy
| | - G. Luppi
- National Cancer Institute-CRO, Aviano, Italy; National Institute for Cancer Research, Genova, Italy; University Hospital, Modena, Italy; University Hospital, Padova, Italy; Ospedali Riuniti, Bergamo, Italy; General Hospital, Ancona, Italy
| | - M. L. Friso
- National Cancer Institute-CRO, Aviano, Italy; National Institute for Cancer Research, Genova, Italy; University Hospital, Modena, Italy; University Hospital, Padova, Italy; Ospedali Riuniti, Bergamo, Italy; General Hospital, Ancona, Italy
| | - G. Beretta
- National Cancer Institute-CRO, Aviano, Italy; National Institute for Cancer Research, Genova, Italy; University Hospital, Modena, Italy; University Hospital, Padova, Italy; Ospedali Riuniti, Bergamo, Italy; General Hospital, Ancona, Italy
| | - S. Delprete
- National Cancer Institute-CRO, Aviano, Italy; National Institute for Cancer Research, Genova, Italy; University Hospital, Modena, Italy; University Hospital, Padova, Italy; Ospedali Riuniti, Bergamo, Italy; General Hospital, Ancona, Italy
| | - L. Pasetto
- National Cancer Institute-CRO, Aviano, Italy; National Institute for Cancer Research, Genova, Italy; University Hospital, Modena, Italy; University Hospital, Padova, Italy; Ospedali Riuniti, Bergamo, Italy; General Hospital, Ancona, Italy
| | - S. Frustaci
- National Cancer Institute-CRO, Aviano, Italy; National Institute for Cancer Research, Genova, Italy; University Hospital, Modena, Italy; University Hospital, Padova, Italy; Ospedali Riuniti, Bergamo, Italy; General Hospital, Ancona, Italy
| | - M. Santantonio
- National Cancer Institute-CRO, Aviano, Italy; National Institute for Cancer Research, Genova, Italy; University Hospital, Modena, Italy; University Hospital, Padova, Italy; Ospedali Riuniti, Bergamo, Italy; General Hospital, Ancona, Italy
| | - R. Corvò
- National Cancer Institute-CRO, Aviano, Italy; National Institute for Cancer Research, Genova, Italy; University Hospital, Modena, Italy; University Hospital, Padova, Italy; Ospedali Riuniti, Bergamo, Italy; General Hospital, Ancona, Italy
| |
Collapse
|
25
|
Casali PG, Fumagalli E, Messina A, Spreafico C, Comandini D, Comandone A, De Giorgi U, Frustaci S, Vinaccia V, Marré Brunenghi MC. Tumor response to imatinib mesylate in advanced GIST. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9028] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. G. Casali
- Istituto Nazionale Tumori, Milano, Italy; Ospedale S. Martino, Genova, Italy; Ospedale Gradenigo, Torino, Italy; Ospedale S. Maria delle Croci, Ravenna, Italy; Centro Riferimento Oncologico, Aviano, Italy; Novartis Farma, Origgio, Varese, Italy
| | - E. Fumagalli
- Istituto Nazionale Tumori, Milano, Italy; Ospedale S. Martino, Genova, Italy; Ospedale Gradenigo, Torino, Italy; Ospedale S. Maria delle Croci, Ravenna, Italy; Centro Riferimento Oncologico, Aviano, Italy; Novartis Farma, Origgio, Varese, Italy
| | - A. Messina
- Istituto Nazionale Tumori, Milano, Italy; Ospedale S. Martino, Genova, Italy; Ospedale Gradenigo, Torino, Italy; Ospedale S. Maria delle Croci, Ravenna, Italy; Centro Riferimento Oncologico, Aviano, Italy; Novartis Farma, Origgio, Varese, Italy
| | - C. Spreafico
- Istituto Nazionale Tumori, Milano, Italy; Ospedale S. Martino, Genova, Italy; Ospedale Gradenigo, Torino, Italy; Ospedale S. Maria delle Croci, Ravenna, Italy; Centro Riferimento Oncologico, Aviano, Italy; Novartis Farma, Origgio, Varese, Italy
| | - D. Comandini
- Istituto Nazionale Tumori, Milano, Italy; Ospedale S. Martino, Genova, Italy; Ospedale Gradenigo, Torino, Italy; Ospedale S. Maria delle Croci, Ravenna, Italy; Centro Riferimento Oncologico, Aviano, Italy; Novartis Farma, Origgio, Varese, Italy
| | - A. Comandone
- Istituto Nazionale Tumori, Milano, Italy; Ospedale S. Martino, Genova, Italy; Ospedale Gradenigo, Torino, Italy; Ospedale S. Maria delle Croci, Ravenna, Italy; Centro Riferimento Oncologico, Aviano, Italy; Novartis Farma, Origgio, Varese, Italy
| | - U. De Giorgi
- Istituto Nazionale Tumori, Milano, Italy; Ospedale S. Martino, Genova, Italy; Ospedale Gradenigo, Torino, Italy; Ospedale S. Maria delle Croci, Ravenna, Italy; Centro Riferimento Oncologico, Aviano, Italy; Novartis Farma, Origgio, Varese, Italy
| | - S. Frustaci
- Istituto Nazionale Tumori, Milano, Italy; Ospedale S. Martino, Genova, Italy; Ospedale Gradenigo, Torino, Italy; Ospedale S. Maria delle Croci, Ravenna, Italy; Centro Riferimento Oncologico, Aviano, Italy; Novartis Farma, Origgio, Varese, Italy
| | - V. Vinaccia
- Istituto Nazionale Tumori, Milano, Italy; Ospedale S. Martino, Genova, Italy; Ospedale Gradenigo, Torino, Italy; Ospedale S. Maria delle Croci, Ravenna, Italy; Centro Riferimento Oncologico, Aviano, Italy; Novartis Farma, Origgio, Varese, Italy
| | - M. C. Marré Brunenghi
- Istituto Nazionale Tumori, Milano, Italy; Ospedale S. Martino, Genova, Italy; Ospedale Gradenigo, Torino, Italy; Ospedale S. Maria delle Croci, Ravenna, Italy; Centro Riferimento Oncologico, Aviano, Italy; Novartis Farma, Origgio, Varese, Italy
| |
Collapse
|
26
|
Gherlinzoni F, Picci P, Mercuri M, Bacci G, Frustaci S, De Paoli A, Barbieri E. The evolution of integrated treatment of soft tissue sarcoma at the Rizzoli Orthopaedic Institute. Chir Organi Mov 2004; 89:95-105. [PMID: 15645786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
The authors take into consideration all types of treatment used at the Rizzoli Orthopaedic Institute and in associated centers over the last 40 years for soft tissue sarcoma of the limbs. For each clinical study the most up-to-date results are reported with statistical evaluations. From the first protocol that used adriamycin alone and up to the beginning of the eighties, we then go on to a second-generation study in the nineties that used adriamycin and ifosphamide at a high dosage. The pilot study that was used at the end of the nineties to evaluate the validity of the use of chemotherapy and radiotherapy is considered, as is the study currently being conducted by the Italian Sarcoma Group. Conclusions based on our vast previous experience lead us to believe that adjuvant chemotherapy must be used for all patients with high-risk soft tissue sarcoma within clinical trials.
Collapse
|
27
|
De Paoli A, Bertola G, Boz G, Frustaci S, Massarut S, Innocente R, De Cicco M, Sartor G, Trovò MG, Rossi C. Intraoperative radiation therapy for retroperitoneal soft tissue sarcomas. J Exp Clin Cancer Res 2003; 22:157-61. [PMID: 16767923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Treatment of retroperitoneal soft tissue sarcomas is a difficult clinical problem. Despite the improvement in resection rates in the most recent surgical series, local control still remains the main problem because of the high incidence of local recurrences after surgery. Postoperative radiation therapy has not been always successful because of dose-tolerance of surrounding normal structures, which prevent the delivery of adequate doses of radiation. To overcome this limitations, new therapeutic approaches including external-beam radiation and intraoperative radiation therapy (IORT) have been evaluated at some Institutions. The results of IORT with or without external-beam radiation are reviewed and our experience with preoperative radiation and IORT is reported. As treatment of retroperitoneal sarcomas has evolved into combined modalities including preoperative radiation, maximum surgical resection and IORT, a possible improvement in local control rates has been achieved. However, locoregional failures and the incidence of distant metastases remain a challenge, emphasising the need for further improvement in local and distant treatment. The new phase II trial, activated within the Italian Sarcoma Group, with preoperative concurrent chemo-radiation therapy and IORT is presented.
Collapse
Affiliation(s)
- A De Paoli
- Radiation Oncology, Surgical Oncology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Frustaci S, De Paoli A, Bidoli E, La Mura N, Berretta M, Buonadonna A, Boz G, Gherlinzoni F. Ifosfamide in the Adjuvant Therapy of Soft Tissue Sarcomas. Oncology 2003; 65 Suppl 2:80-4. [PMID: 14586155 DOI: 10.1159/000073366] [Citation(s) in RCA: 139] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Ifosfamide and anthracyclines are the only active agents in advanced soft tissue sarcomas. Doxorubicin was always used in sarcomas, whereas ifosfamide was reintroduced in the clinic after the discovery of mesna which prevents its typical dose-limiting toxicity: hemorrhagic cystitis. In the adjuvant setting, doxorubicin was used alone or in combination in the first-generation trials, whereas its parent compounds epirubicin and ifosfamide were employed in the second-generation adjuvant trials, which started in the early 90s. Other relevant aspects of the second-generation trials are the use of the hematopoietic growth factors and the increase of the dose intensity, the introduction of more restrictive selection criteria and the use of the two most active agents, ifosfamide and anthracyclines. Only the Italian cooperative trial has been concluded, and the results reported and updated. After a median follow-up of 89.6 months (range 56-119), the intention-to-treat analysis still reveals a difference in overall survival which, however, is not statistically significant. However, the 5-year overall survival estimate, which is a reasonable end point for the survival analysis of adjuvant treatment in soft tissue sarcomas, was 66.0 and 46.1% for the treatment and the control groups, respectively (p = 0.04).
Collapse
Affiliation(s)
- S Frustaci
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano, General Hospital, Gorizia, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
De Paoli A, Rossi C, Boz G, Innocente R, Bertola G, Massarut S, De Cicco M, Sartor G, Frustaci S, Trovo’ M. Preoperative and intraoperative radiation therapy for retroperitoneal soft tissue sarcomas: preliminary results of a pilot study. Int J Radiat Oncol Biol Phys 2003. [DOI: 10.1016/s0360-3016(03)01421-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
30
|
Stefanovski PD, Bidoli E, De Paoli A, Buonadonna A, Boz G, Libra M, Morassut S, Rossi C, Carbone A, Frustaci S. Prognostic factors in soft tissue sarcomas: a study of 395 patients. Eur J Surg Oncol 2002; 28:153-64. [PMID: 11884051 DOI: 10.1053/ejso.2001.1242] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
AIMS The aim of this study was to report prognostic factors, end-points of local recurrence, distant recurrence, post-metastasis survival, and overall survival in a cohort of patients with soft tissue sarcomas. METHODS We analysed a database of 395 patients affected by primary soft tissue sarcomas of various primary sites, treated and followed up at the Centro di Riferimento Oncologico, Aviano, Italy from January 1985 to January 1997. RESULTS Grade, size, stage, surgical margins, distant metastasis, age, sex, performance status, and haemoglobin value were significant for overall survival. Histology, grade, stage, and surgical margins were significant for local recurrence. Grade, size, and stage, were significant for distant recurrence; and surgical margin was significant variable for post-metastasis survival. CONCLUSIONS Grade, size, and TNM stage (UICC/AJCC) have stronger prognostic significance for overall survival and distant recurrence than for local relapse. Positive surgical margins are the main predictors for local relapse. Age was the most consistent adverse independent prognostic factor for survival.
Collapse
Affiliation(s)
- P D Stefanovski
- Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Bearz A, Giometto B, Freschi A, Gobitti C, Scalone S, Sorio R, Frustaci S, Berretta M, Nicolao P, Cartei G. Occult Small Cell Lung Cancer Associated with Paraneoplastic Neurologic Syndrome: Case Report. Tumori 2001; 87:447-50. [PMID: 11989604 DOI: 10.1177/030089160108700619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cancer is often associated with paraneoplastic syndromes, which may be misinterpreted. We report a case of a patient with occult small cell lung cancer that was initially compounded by clinical features of a paraneoplastic neurologic syndrome. The presence of antineuronal antibodies and positron emission tomography scan guided the search for the underlying tumor. Following chemo-radiotherapy the patient showed no evidence of disease for the next 18 months, whereas only a slight improvement in the neurologic disorders was observed. The course of the small cell lung cancer was very indolent and the paraneoplastic neurologic syndrome did not worsen with the use of cisplatin.
Collapse
Affiliation(s)
- A Bearz
- Department of Medial Oncology B, CRO-IRCSS, National Cancer Institute, Aviano, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001; 19:1238-47. [PMID: 11230464 DOI: 10.1200/jco.2001.19.5.1238] [Citation(s) in RCA: 451] [Impact Index Per Article: 19.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
PURPOSE Adjuvant chemotherapy for soft tissue sarcoma is controversial because previous trials reported conflicting results. The present study was designed with restricted selection criteria and high dose-intensities of the two most active chemotherapeutic agents. PATIENTS AND METHODS Patients between 18 and 65 years of age with grade 3 to 4 spindle-cell sarcomas (primary diameter > or = 5 cm or any size recurrent tumor) in extremities or girdles were eligible. Stratification was by primary versus recurrent tumors and by tumor diameter greater than or equal to 10 cm versus less than 10 cm. One hundred four patients were randomized, 51 to the control group and 53 to the treatment group (five cycles of 4'-epidoxorubicin 60 mg/m(2) days 1 and 2 and ifosfamide 1.8 g/m(2) days 1 through 5, with hydration, mesna, and granulocyte colony-stimulating factor). RESULTS After a median follow-up of 59 months, 60 patients had relapsed and 48 died (28 and 20 in the treatment arm and 32 and 28 in the control arm, respectively). The median disease-free survival (DFS) was 48 months in the treatment group and 16 months in the control group (P =.04); and the median overall survival (OS) was 75 months for treated and 46 months for untreated patients (P =.03). For OS, the absolute benefit deriving from chemotherapy was 13% at 2 years and increased to 19% at 4 years (P =.04). CONCLUSION Intensified adjuvant chemotherapy had a positive impact on the DFS and OS of patients with high-risk extremity soft tissue sarcomas at a median follow-up of 59 months. Therefore, our data favor an intensified treatment in similar cases. Although cure is still difficult to achieve, a significant delay in death is worthwhile, also considering the short duration of treatment and the absence of toxic deaths.
Collapse
Affiliation(s)
- S Frustaci
- Unità Operativa di Oncologia Medica and di Oncologia Radioterapica and the Servizio di Epidemiologia, Centro di Riferimento Oncologico, Aviano, Italy. sfrustaci.cro.it
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Favaretto A, Ceresoli GL, Paccagnella A, Barbieri F, Bearz A, Ghiotto C, Oniga F, Schiavon S, Frustaci S, Villa E. Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV). Ann Oncol 2000; 11:1421-6. [PMID: 11142482 DOI: 10.1023/a:1026527004596] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The combination of paclitaxel (P) and carboplatin (C) is an effective treatment for advanced NSCLC. Gemcitabine (G) is an active new drug. We planned a phase I study to find the maximum tolerated dose (MTD) of the PCG combination. A phase II study was subsequently conducted to evaluate the activity and toxicity of PCG. PATIENTS AND METHODS Forty-five patients entered the study. Twenty-eight had stage IIIA-B disease, 17 stage IV. In the phase I study, with a fixed dose of C at AUC = 6 on day 1, P was escalated using increments of 25 mg/m2 starting from 175 mg/m2 on day 1 and G with increments of 200 mg/m2 starting from 800 mg/m2 on day 1 and 8. RESULTS Fourteen patients entered the phase I study. The MTD was reached at P 200 mg/m2, C AUC = 6 and G 1000 mg/m2. Neutropenic fever and grade 3 diarrhea were the dose limiting toxicities. Thirty-one patients were treated in the phase II study with P 175 mg/m2, C AUC = 6 and G 1000 mg/m2. Response rate was 57% (68% in stage III and 47% in stage IV). Myelosuppression was the main toxicity, with grade 3-4 leukopenia occurring in 35% of cases. Grade 3 anemia was observed in 24% of cases and grade 3-4 thrombocytopenia occurred in 34% of patients. Non-hematological toxicity was mild. Median survival and one-year actuarial survival were 20.5 months and 74% for stage III and 11.5 months and 47% for stage IV. CONCLUSIONS PCG is a promising regimen for treating advanced NSCLC. A phase III study comparing PCG to paclitaxel plus carboplatin in advanced NSCLC is ongoing. On the other hand, we are planning to introduce the PCG regimen in the treatment of stage II-III patients in the setting of a multimodality treatment.
Collapse
Affiliation(s)
- A Favaretto
- Medical Oncology Department, Azienda Ospedaliera Padova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Lo Re G, Buonadonna A, Duati M, Colussi AM, Canzonieri V, Frustaci S, Morassut S, Cimitan M, Tumolo S. Efficacy of Total Androgen Blockade in Metastatic Prostatic Carcinoma with Transient Hypogonadotropic Hypogonadism: A Case Report. Tumori 1999; 85:280-3. [PMID: 10587032 DOI: 10.1177/030089169908500413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A patient affected by metastatic prostatic carcinoma and hypogonadotropic hypogonadism (HH) was treated with flutamide 750 mg/day plus an LH-RH analog. After confirmation of basal castration during treatment, he continued with antiandrogens alone. Following the normalization of gonadic function and subjective mild bone flare-up, the patient resumed the initial treatment and obtained a partial response. When flutamide was interrupted because of liver toxicity, the patient showed progressive disease in the bone, which was unresponsive to both flutamide resumption and salvage hormone therapy (bicalutamide). The patient is currently receiving chemotherapy with VP16 and estramustine phosphate and is showing both serologic (PSA) and symptomatic response. The interest of this case lies in the incidental detection of HH during therapy and in the responsiveness to treatment.
Collapse
Affiliation(s)
- G Lo Re
- Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Comandone A, Leone L, Oliva C, Frustaci S, Monteleone M, Colussi AM, Dal Canton O, Bergnolo P, Boglione A, Bumma C. Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. J Chemother 1998; 10:385-93. [PMID: 9822357 DOI: 10.1179/joc.1998.10.5.385] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Ifosfamide is a leading drug in soft tissue sarcoma therapy. Recently high dose therapy (>9 g/m2) has been introduced in different schemes to obtain a higher response rate. All these higher doses can be administered following two different schedules: continuous infusion 24 hours a day for 4-5 days or bolus administration for 5 consecutive days. In this study we compare the differences in the pharmacokinetic profile between the two schedules. In both schemes we saw a very important autoinduction phenomenon, with a corresponding half-life decrease and total body clearance increase during the days of therapy. The clearances were not directly correlated with the administered dose. We can conclude that ifosfamide continuous infusion therapy is equivalent to fractionated administration, at least from a pharmacokinetic point of view. Short-term infusion is subjectively better tolerated and is therefore preferred.
Collapse
Affiliation(s)
- A Comandone
- Department of Clinical Oncology, San Giovanni Antica Sede Hospital, Turin, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
AIMS In an attempt to reverse multidrug resistance, in a recent trial of verapamil in association with doxorubicin, we used escalating doses of continuous intravenous (i.v.) verapamil under close haemodynamic monitoring. We report the pharmacokinetics of escalating doses of verapamil. METHODS We studied nine patients [seven males, two females; median age 46 years (range, 31-57)] with advanced adenocarcinoma of the colon and normal renal, hepatic, and cardiac functions. After a loading dose (0.15 mg kg-1 followed by 12 h continuous i.v. infusion at 0.20 mg kg-1 h-1), the infusion rate (ko) of verapamil was increased every 24 h (0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1). The highest rate was maintained for 48 h. Doxorubicin was given as a continuous i.v. infusion from 12 to 108 h (n = 4) or 60 to 108 h (n = 5). Blood samples and urine collections were taken every 12 h. Verapamil and nor-verapamil were assayed by high performance liquid chromatography. We calculated systemic clearance of verapamil (CL = ko/Css) and renal clearance (CLr) of verapamil and nor-verapamil. The Css vs rate relationship was fitted to a Michaelis-Menten equation: Css = ko. (K(m)+Css)/(V.Vm). RESULTS CL was dose-dependent and in all nine patients a significant reduction in CL was observed over the dose range (mean CL +/- s.d. were 0.51 +/- 0.31, 0.38 +/- 0.16, 0.32 +/- 0.18, and 0.27 +/- 0.11 l h-1 kg-1, respectively, at 0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1; P = 0.0001). Css increased more than proportionally to the dose rate and the Css vs rate relationship was best defined by a Michaelis-Menten equation (K(m) = 730 micrograms l-1; V.Vm = 0.55 mg kg-1 h-1), (r = 0.994; P = 0.006). CLr of verapamil and nor-verapamil was not saturable but the contribution to the elimination was only 2 to 4% of the dose. CONCLUSIONS These findings suggest a non-linear, capacity-limited metabolic clearance of high-dose verapamil. Using escalating infusion rates, high verapamil concentrations (1500-2500 ng ml-1) were achieved without major toxicity. Saturable clearance may cause higher bioavailability and slower elimination of verapamil after acute oral overdoses.
Collapse
Affiliation(s)
- G Toffoli
- Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Verusio C, Romanini A, Frustaci S, Comandone A, De Toma D, Dogliottl L, Piolini M, lionetto R, Dani C, Santoro A. Phase II study with Docetaxel (Taxotere) as second line treatment of advanced soft tissues sarcomas in adult. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)85007-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
38
|
Frustaci S, Buonadonna A, Galligioni E, Favaro D, De Paoli A, Lo Re G, Sorio R, Tumolo S, Monfardini S. Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. J Clin Oncol 1997; 15:1418-26. [PMID: 9193334 DOI: 10.1200/jco.1997.15.4.1418] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
PURPOSE To determine the maximum-tolerated dose (MTD) of 4'-epidoxorubicin (EPI) in combination with full dose of ifosfamide (IFO) when granulocyte-macrophage colony-stimulating factor (GM-CSF) was used, to estimate its clinical efficacy, and to evaluate the mobilization of hematopoietic progenitors. PATIENTS AND METHODS Previously untreated advanced patients were treated with fixed doses of IFO at 1.8 g/m2/d for 5 days and escalating doses of EPI. The starting dose level of EPI was 50 mg/m2 bolus on days 1 and 2; subsequent levels were 60 mg/m2 and 70 mg/ m2 given on days 1 and 2. GM-CSF (5 micrograms/kg/d) was administered from days +6 to +19. Clinical evaluation of response was performed after three consecutive cycles. Mobilization of hematopoietic progenitors was evaluated as day 14 CFU-GM after the first cycle only. RESULTS Overall, six, 18, and 13 assessable patients were entered onto each EPI dose level, respectively. The first and the second EPI level were considered feasible. Conversely, at the third level, only six of 13 patients [46%] tolerated full EPI doses at the scheduled time. Therefore, the dose-intensity of the three levels was 100%, 99.7%, and 86.1%, respectively. Overall, 20 of 37 patients (54%) obtained an objective response. The response rates for the three EPI dose levels were significantly different [17%, 33%, and 100%, respectively; test for trend, P < .001]. Considering only lung metastases, the overall response rate was 72% (20%, 66%, and 100% for the three EPI levels, respectively). The most relevant mobilization effect was obtained at the third EPI level, when both GM-CSF and IL-3 were used as in vitro-stimulating factors. CONCLUSION The third EPI level (70 mg/m2 on days 1 and 2) is the MTD of this program, since it was administered, without dose reduction or treatment delay, for three consecutive cycles in less than half of the patients. Nevertheless, this level proved to be interesting with regard to response rate (13 of 13 objective responses) and in mobilization of the hematopoietic progenitors.
Collapse
Affiliation(s)
- S Frustaci
- Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Crivellari D, Buonadonna A, Frustaci S, Tumolo S, Magri M, De Paoli A, Sigon R, Rossi C, Monfardini S. 136 P - Feasibility and activity of a 3-day pelf-like regimen in advanced gastric cancer. Preliminary data. Eur J Cancer 1996. [DOI: 10.1016/0959-8049(96)84895-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
Frustaci S, Zmerly H, Buonadonna A, Barbieri E, Olmi P, Comandone A, Azzarelli A, Apice G, Ferrari S, De Paoli A, Picci P, Gherlinzoni F. 856 Intensified adjuvant chemotherapy for extremity soft tissue sarcomas (STS). Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)96105-m] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
41
|
Comandone A, Frustaci S, Leone L, Santoro A, Oliva C, Bretti S, verusio C, Colussi A, Bumma C. 853 Ifosfamide in continuous infusion: The pharmacokinetic profile in patients with soft tissue sarcomas. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)96102-j] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
42
|
Buonadonna A, Romanini A, Comandone A, Della Palma M, Verusio C, Lionerto R, Frustaci S. 857 Increasing continuous infusion (C.I.) ifosfamide (IFO) and bolus epirubicin (EPI) in soft tissue sarcoma (STS) patients (PTS). Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)96106-n] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
43
|
Toffoli G, Vinante O, Rosetti F, Azzarello G, Gigante M, Zanuttini D, Viel M, Nicolosi GL, Sartori F, Pascotto P, Fantin D, Frustaci S, Boiocchi M. Racemic verapamil (VER) as a chemosensitizer agent of doxorubicin (DOX) in human colorectal cancer (HCC). Anticancer Drugs 1994. [DOI: 10.1097/00001813-199409001-00144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Toffoli G, Doglioni C, Cernigoi C, Frustaci S, Perin T, Canal B, Boiocchi M. P53 overexpression in human soft tissue sarcomas: relation to biological aggressiveness. Ann Oncol 1994; 5:167-72. [PMID: 8186161 DOI: 10.1093/oxfordjournals.annonc.a058771] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND The tumor suppressor protein p53 is overexpressed in a large fraction of human tumors. It has been supposed that p53 abnormalities may be an early event that contributes to the neoplastic transformation; alternatively, p53 overexpression might be related to progression toward more aggressive tumor phenotypes. The aim of the present work was to better clarify the role of p53 overexpression in human soft tissue sarcomas (IISTS). DESIGN p53 immunohistochemistry analysis using the Pab 1801 was performed in frozen samples of HSTS obtained from 61 patients. Tumors were classified according to the WHO criteria, histologic grading was based on the criteria of Enzinger and Weiss, and DNA ploidy and S-phase determination was performed by flow cytometrical analysis. RESULTS Of all the HSTS we analyzed, p53 protein over-expression occurred more frequently in G3 grade tumors (p < 0.01), HSTS of III A-B stage (p = 0.02) and in aneuploid tumors (p < 0.01). CONCLUSIONS The association of p53 overexpression with parameters of biological aggressiveness suggests an involvement of p53 in the neoplastic progression of HSTS. This assumption is supported by the findings that in tumors with a mixed diploid/aneuploid neoplastic cell population p53 protein expression was significantly (p < 0.01) higher in the aneuploid cell subpopulation. In conclusion, our study suggests that overexpression of p53 is present mainly in the most biologically aggressive forms of HSTS and may therefore represent a neoplastic progression index possibly useful for prognostic purposes.
Collapse
Affiliation(s)
- G Toffoli
- Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano (PN), Italy
| | | | | | | | | | | | | |
Collapse
|
45
|
Frustaci S, Foladore S, Buonadonna A, De Paoli A, Crivellari D, Carbone A, Sorio R, Morassut S, Monfardini S. Epirubicin and ifosfamide in advanced soft tissue sarcomas. Ann Oncol 1993; 4:669-72. [PMID: 8240997 DOI: 10.1093/oxfordjournals.annonc.a058622] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients. PATIENTS AND METHODS Treatment consisted of: epirubicin 75 mg/m2 i.v. day 1; IFO 1.8 g/m2 days 1 to 5; MESNA 20% of the IFO dose at 4-hour intervals three times a day during IFO administration. Cycles were given every 3-4 weeks for at least three cycles. RESULTS The overall response rate for non-visceral sarcomas (51 pts) was 31% (95% confidence limits +/- 13%). Among the 13 visceral sarcomas no response was seen for the leiomyosarcomas of the gastrointestinal tract, whereas one complete and one partial remission were observed for the uterine sarcomas. The duration of response was 10 months (range 5-34+) for complete responses and 9 (range 4-42+) for partial responses. The median survival for responders is 18 months (range 2-60+) and for non-responders 10 months (range 1-33) (p < 0.004). CONCLUSIONS This combination proved to be feasible and tolerable. The overall response rate does not appear to be superior to those with other standard treatments, but it should be pointed out that our patient population was totally unselected.
Collapse
Affiliation(s)
- S Frustaci
- Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Frustaci S, Foladore S, De Pascale A, Freschi A, Lo Re G, Sorio R, Errante D, Monfardini S. Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO). Ann Oncol 1992; 3 Suppl 2:S115-8. [PMID: 1622852 DOI: 10.1093/annonc/3.suppl_2.s115] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Tolerability and efficacy of the new uroprotective agent ARGIMESNA was assessed within a randomized cross-over study comparing it to sodiummercaptoethanesulfonate (MESNA), in patients treated with IFO. MESNA i.v., 20% of IFO dose, was given to all patients before chemotherapy; 4 h later, at random, they received ARGIMESNA p.o., 20% of IFO dose every 2 h x 4, or MESNA p.o., 40% of IFO dose every 4 h x 2. Overall, 78 cycles of oral uroprotection were administered: 37 for ARGIMESNA capsules; 41 for MESNA vials p.o. ARGIMESNA was subjectively better tolerated, determining gastro-intestinal discomfort in only 12 out of 37 cycles versus 34/41 of MESNA p.o. (p less than 0.001). Both preparations were equivalent for subjective and objective efficacy since no cycles were complicated by urinary symptoms (dysuria, stranguria, or hematuria). Nevertheless, 2 patients (7.7%) refused further oral assumption of both uroprotectors, whereas MESNA i.v. was added in other 7 patients because of nausea and vomiting caused by chemotherapy. In conclusion, this new oral preparation of mercaptoethanesulfonate turned out to be well tolerated, safe and active in the prevention of haemorrhagic cystitis from IFO.
Collapse
Affiliation(s)
- S Frustaci
- Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | | | | | | | |
Collapse
|
47
|
De Paoli A, Bertola G, Boz G, Gherlinzoni F, Frustaci S, Fumo G, Innocente R, Trovò MG, Rossi C, Carbone A. Radiation therapy and conservative surgery for soft tissue sarcomas of the extremities, torso and head and neck. Ann Oncol 1992; 3 Suppl 2:S97-101. [PMID: 1622879 DOI: 10.1093/annonc/3.suppl_2.s97] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Between May 1985 and July 1990, 45 patients (pts.) with primary (39) or recurrent (6) soft tissue sarcomas of the extremities (82%), torso (11%) and head and neck (7%) were treated with radiation therapy and conservative surgery. Seven pts. not amenable to conservative surgery underwent preoperative radiation therapy whereas 38 pts. underwent local excision and post-operative radiation therapy. Out of the 38 pts. managed by postoperative radiation, 24 (63%) showed negative surgical margins and 14 (37%) positive margins, their tumor being adjacent to vital structures. Preoperative radiation allowed conservative surgery in all 7 pts. with initially inoperable tumor; surgical margins were negative in 5 and positive in 2 pts. Twenty-six pts. (58%) had tumor greater than or equal to 5 cm (5-24) and 19 (42%) less than 5 cm (2.5-4.5) in diameter. High grade tumors (G2-G3) were reported in 41 pts. (90%). In pts. treated postoperatively the radiation dose was 64-66 Gy/32-33 fractions and the pts. treated preoperatively received a dose of 50 Gy/25 fractions. Median follow-up was 33 months and all pts. had a minimum follow-up of 12 months (12-72). Three pts. (6.5%) had local failure and 9 (20%) developed distant metastases with local tumor control. All distant metastases occurred in AJC stage IIIB, 9/18 (50%), with an increased frequency by tumor size. Overall local control and disease free survival rates at 5 years (product-limit method) were 93% and 73%, respectively. An evident decrease in disease-free survival rate (33%) was noted for stage IIIB pts.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- A De Paoli
- Radiotherapy Division, Centro di Riferimento Oncologico (C.R.O.), Aviano, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Toffoli G, Frustaci S, Tumiotto L, Talamini R, Gherlinzoni F, Picci P, Boiocchi M. Expression of MDR1 and GST-pi in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness. Ann Oncol 1992; 3:63-9. [PMID: 1606072 DOI: 10.1093/oxfordjournals.annonc.a058073] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Human soft tissue sarcomas (HSTS) in adults are a family of mesenchymal tumors characterized by high biological aggressiveness and general refractoriness to chemotherapy. A series of 36 HSTS, 24 untreated and 12 homogeneously treated with a presurgical chemotherapeutic regimen consisting of doxorubicin (intra-arterial) and iphosphamide (intra-vein), was analyzed for expression of MDR1 and the glutathione-S-transferase-pi (GST-pi) gene in order to identify molecular phenomena which may be implicated in the chemoresistance displayed by these tumors. The MDR1 gene was expressed in a greater percentage of drug-treated tumors and at higher levels than in untreated ones. By contrast, chemotherapeutic treatment has no effect on GST-pi mRNA expression. The GST-pi expression level (EL) was much higher in the HSTS with biologically aggressive features. In fact, significant correlations were observed between GST-pi and histologic grade (p = 0.01); aneuploidy (p less than 0.01); and histone H3 EL (p = 0.01), suggesting a possible causal relationship between GST-pi activity and biological aggressiveness in HSTS.
Collapse
Affiliation(s)
- G Toffoli
- Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | | | | | |
Collapse
|
49
|
Sessa C, Zucchetti M, Davoli E, Califano R, Cavalli F, Frustaci S, Gumbrell L, Sulkes A, Winograd B, D'Incalci M. Phase I and clinical pharmacological evaluation of aphidicolin glycinate. J Natl Cancer Inst 1991; 83:1160-4. [PMID: 1886148 DOI: 10.1093/jnci/83.16.1160] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
The toxicity profile and the pharmacokinetics of aphidicolin glycinate, a water-soluble analogue of aphidicolin, have been evaluated in two consecutive phase I clinical studies. In the first study, aphidicolin glycinate was given by 1-hour infusion for 5 consecutive days, every 3 weeks (daily x 5 study); in the second study, which was planned on the basis of the pharmacokinetic information obtained in the previous study, the drug was given by 24-hour continuous infusion. Treatment was repeated every 3 weeks. In the daily x 5 study, the daily dose was escalated from 12 mg/m2 to the maximum tolerated dose of 2250 mg/m2. Local toxicity was dose limiting. Elimination half-life was 2 +/- 0.2 hours (mean +/- SE) with aphidicolin being undetectable 6-8 hours after the end of the infusion. In the 24-hour continuous-infusion study, the dose was escalated from 435 mg/m2 to the maximum tolerated dose of 4500 mg/m2. Local toxicity was dose limiting, while other toxic effects were absent. The experimentally determined concentrations at the steady state were in agreement with those predicted on the basis of the available pharmacokinetic data. The targeted concentration at the steady state of 3 micrograms/mL was achieved at doses greater than or equal to 3000 mg/m2. Twenty-four-hour continuous infusion is the recommended schedule for clinical evaluations of aphidicolin glycinate as the synchronizing agent or in combination with cisplatin.
Collapse
Affiliation(s)
- C Sessa
- Servizio Oncologico, Ospedale San Giovanni, Bellinzona, Switzerland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Frustaci S, Barzan L, Caruso G, Ghirardo R, Foladore S, Carbone A, Comoretto R, Serafini I, Monfardini S. Induction intra-arterial cisplatin and bleomycin in head and neck cancer. Head Neck 1991; 13:291-7. [PMID: 1714433 DOI: 10.1002/hed.2880130405] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Fifty-two consecutive patients, affected by large T2 (greater than 3 cm), T3, T4, N0, or N1 previously untreated squamous cell carcinoma of the head and neck, entered this phase I-II study. Treatment consisted of a continuous 8-day infusion on the following daily schedule: cisplatin 25 mg and bleomycin 15 mg administered for 4 and 20 hours, respectively. Technical-related toxicities were 1 case each of coagulation and displacement of the catheter and 1 case of reversible monoparesis of the contralateral arm. Drug-related relevant toxicities accounted for 4 cass of grade 3 or 4 leukopenia and 2 cases of peripheral palsy of the 7th and 12th cranial nerve, respectively. Forty-five of 50 evaluable patients obtained an objective response. In particular, 13 patients obtained a complete response, 22 a partial response greater than or equal to 75%, and 10 a partial response greater than or equal to 50%. Furthermore, 5 of 31 patients showed a complete pathologic disappearance of the tumor, whereas in 12 of 31 only a microscopic residue was found.
Collapse
Affiliation(s)
- S Frustaci
- Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|